Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
KRd versus VRd in patients with newly diagnosed multiple myeloma

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 1034

Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA

Dr Ola Landgren speaks to ecancer at ASH 2018 about the results from a study into carfilzomib-lenalidomide-dexamethasone (KRd) versus bortezomib-lenalidomide-dexamethasone (VRd) in newly diagnosed patients with multiple myeloma.

He explains that the CoMMpass study, launched by the Multiple Myeloma Research Foundation (MMRF), can be used to identify patients treated with the KRd and VRd regiments.

Dr Landgren reveals that the event free survival is highly superior for patients treated with KRd.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation